Hookipa Pharma 

$1.19
35
+$0.01+0.85% Tuesday 19:20

Statistics

Day High
1.2
Day Low
1.18
52W High
1.75
52W Low
0.82
Volume
6,200
Avg. Volume
-
Mkt Cap
11.82M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

27FebExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
-1.95
-1.5
-1.06
-0.61
Expected EPS
-0.76
Actual EPS
N/A

Financials

-98.99%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
87.89MRevenue
-87.01MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HOOK. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap17.99B
Moderna is a leader in mRNA technology, competing in the infectious disease and cancer vaccine space similar to Hookipa Pharma's focus on arenavirus-based therapies.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech competes directly with Hookipa Pharma in the development of novel vaccines for infectious diseases and cancer, leveraging mRNA technology.
Novavax
NVAX
Mkt Cap1.32B
Novavax is a competitor in the vaccine space, focusing on developing vaccines for infectious diseases, a direct competition to Hookipa's infectious disease program.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences competes with Hookipa Pharma in the oncology and infectious disease market, particularly through its cell therapies and antiviral drugs.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes across a broad range of therapeutic areas including vaccines for infectious diseases, directly competing with Hookipa Pharma's vaccine development efforts.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its Janssen Pharmaceuticals division, competes in the infectious disease and cancer markets, areas of focus for Hookipa Pharma.
Merck
MRK
Mkt Cap277.02B
Merck is a competitor in the development of vaccines and therapies for infectious diseases and cancer, aligning with Hookipa Pharma's areas of focus.
Incyte
INCY
Mkt Cap19.36B
Incyte competes with Hookipa Pharma in the oncology sector, particularly in developing novel therapeutics for cancer treatment.
AMGEN
AMGN
Mkt Cap178B
Amgen competes in the biopharmaceutical space focusing on innovative therapeutics for cancer and infectious diseases, overlapping with Hookipa Pharma's research areas.

About

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Show more...
CEO
Dr. Malte Peters M.D.
Employees
82
Country
United States
ISIN
US43906K2096

Listings

0 Comments

Share your thoughts

FAQ

What is Hookipa Pharma stock price today?
The current price of HOOK is $1.19 USD — it has increased by +0.85% in the past 24 hours. Watch Hookipa Pharma stock price performance more closely on the chart.
What is Hookipa Pharma stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Hookipa Pharma stocks are traded under the ticker HOOK.
Is Hookipa Pharma stock price growing?
HOOK stock has risen by +2.59% compared to the previous week, the month change is a +3.48% rise, over the last year Hookipa Pharma has showed a -19.59% decrease.
What is Hookipa Pharma market cap?
Today Hookipa Pharma has the market capitalization of 11.82M
What is Hookipa Pharma revenue for the last year?
Hookipa Pharma revenue for the last year amounts to 87.89M USD.
What is Hookipa Pharma net income for the last year?
HOOK net income for the last year is -87.01M USD.
How many employees does Hookipa Pharma have?
As of May 06, 2026, the company has 82 employees.
In which sector is Hookipa Pharma located?
Hookipa Pharma operates in the Health & Wellness sector.
When did Hookipa Pharma complete a stock split?
The last stock split for Hookipa Pharma was on July 10, 2024 with a ratio of 1:10.
Where is Hookipa Pharma headquartered?
Hookipa Pharma is headquartered in New York, United States.